CD19 and neoplasm: Interestingly, iC9-CD19.ζ-MC-modified T cells showed a decrease in PD-1 expression compared with a first-generation CAR, suggesting that constitutive MC activity may reduce the sensitivity of iC9-CD19.ζ-MC T cells to PD-L1 expression in the tumor microenvironment (Fig. 2h).